Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
There is no widely accepted standard for antifungal prophylaxis in patients with hematologic malignancies. The Infectious Diseases Working Party of the German Society for Haematology and Oncology assigned a committee of hematologists and infectious disease specialists to develop recommendations. Literature data bases were systematically searched for clinical trials on antifungal prophylaxis. The studies identified were shared within the committee. Data were extracted by two of the authors (OAC and MSi). The consensus process was conducted by email communication. Finally, a review committee discussed the proposed recommendations. After consensus was established the recommendations were finalized. A total of 86 trials were identified including 16,922 patients. Only a few trials yielded significant differences in efficacy. Fluconazole 400 mg/d improved the incidence rates of invasive fungal infections and attributable mortality in allogeneic stem cell recipients. Posaconazole 600 mg/d reduced the incidence of IFI and attributable mortality in allogeneic stem cell recipients with severe graft versus host disease, and in patients with acute myelogenous leukemia or myelodysplastic syndrome additionally reduced overall mortality. Aerosolized liposomal amphotericin B reduced the incidence rate of invasive pulmonary aspergillosis. Posaconazole 600 mg/d is recommended in patients with acute myelogenous leukemia/myelodysplastic syndrome or undergoing allogeneic stem cell recipients with graft versus host disease for the prevention of invasive fungal infections and attributable mortality (Level A I). Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244
Prophylactic antifungal therapy in the intensive care unit
Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases · doi:10.1086/319763 · Cited by 155
Cited by
Koehler, P., Hamprecht, A., Bader, O., Bekeredjian-Ding, I., Buchheidt, D., Doelken, G., Elias, J., Haase, G., Hahn-Ast, C., Karthaus, M., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.10.019 · Cited by 91
Self-citationWinston, D. J., Bartoni, K., Territo, M. C., & Schiller, G. J. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.04.017 · Cited by 73
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
Vazquez, L. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.040 · Cited by 34
Metadata
- Authors
- Cornely, O. A., Bohme, A., Buchheidt, D., Einsele, H., Heinz, W. J., Karthaus, M., Krause, S. W., Kruger, W., Maschmeyer, G., Penack, O., Ritter, J., Ruhnke, M., Sandherr, M., Sieniawski, M., Vehreschild, J.-J., Wolf, H.-H., & Ullmann, A. J.
- Venue
- Haematologica
- Published
- 2009-01-01
- Volume
- 94
- Issue
- 1
- Pages
- 113-122
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2144423069
- Cited by
- 178
- References
- 5
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. https://app.cochat.ai/papers/10.3324/haematol.11665
- The paper
- Cornely, O. A., Bohme, A., Buchheidt, D., Einsele, H., Heinz, W. J., Karthaus, M., Krause, S. W., Kruger, W., Maschmeyer, G., Penack, O., Ritter, J., Ruhnke, M., Sandherr, M., Sieniawski, M., Vehreschild, J.-J., Wolf, H.-H., & Ullmann, A. J. (2009). Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. https://doi.org/10.3324/haematol.11665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.